OraSure Technologies, Inc.

NASDAQ:OSUR

Medical - Instruments & Supplies

Healthcare
$3.59 -3.47%

-$0.16 today

Market cap
$247.88M
Beta
1.01
P/E (TTM)
-4.0
EPS (TTM)
-$1.08
52W Low $2.08High $4.58

Volume 0.49M

Average 0.61M

OSUR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

OraSure Technologies, Inc.NASDAQ: OSUR

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$20.47M, compared with -$13.73M a year earlier. Trailing-twelve-month EBITDA was -$63.7M.

Context

  • EBITDA amounted to 49.5% of revenue in FY2025, up 45.8 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$33.39M (+41.4%) for the fiscal year ending Dec 2026, a step up from the -734.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$20.47M-22.8% QoQ
Last fiscal yearDec 2025
-$56.96M-734.1% YoY
LTMMar 2026
-$63.7M-188.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.1%-5.9%+43.2 pp
1 year-734.1%+41.4%+775.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(56.96M) USD
Year-over-year change
-734.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How OSUR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -188.7% is the lowest of 9, against a peer median of -0.0%.
  • EBITDA amounts to 56.4% of revenue for OSUR, versus a peer median of 123.0%.
OSUR Competitors
EBITDA for OSUR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTMDUtah Medical Products, Inc.LTM Mar 2026$16.36M USD-9.1%-15.0%43.6%
STIMNeuronetics, Inc.LTM Mar 2026-$25.7M USD+34.0%—17.0%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026-$35.22M USD———
PROFProfound Medical Corp.LTM Mar 2026-$37.85M USD+9.1%—200.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026-$50.77M USD+11.7%——
PREPrenetics Global LimitedLTM Mar 2026-$51.68M USD+9.1%—45.4%
TARAProtara Therapeutics, Inc.LTM Mar 2026-$62.94M USD-39.6%——
OSUROraSure Technologies, Inc.LTM Mar 2026-$63.7M USD-188.7%—56.4%
NYXHNyxoah S.A.LTM Mar 2026-€77.16M EUR-21.4%—472.8%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$110.64M USD-31.7%—17902.8%
Peer median (excluding OSUR) —-0.0%-15.0%123.0%

Competitors are the stored peer set for OSUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue233.67M387.48M405.47M185.83M115.02M
Cost of Revenue116.07M239.04M226.05M109.6M66.82M
Gross Profit117.6M148.44M179.42M76.23M48.2M
Gross Margin50.3%38.3%44.2%41.0%41.9%
Research & Development34.17M36.24M33.16M24.42M42.53M
Selling, General & Admin95.08M117.44M92.18M72.41M73.79M
Operating Expenses129.25M153.68M125.34M96.83M116.32M
Depreciation & Amortization11.66M14M19.9M10.87M9.97M
EBITDA2.37M(1.68M)76.16M(6.83M)(56.96M)
EBITDA Margin1.0%-0.4%18.8%-3.7%-49.5%
Operating Income(11.65M)(5.24M)54.08M(20.6M)(68.12M)
Operating Margin-5.0%-1.4%13.3%-11.1%-59.2%
Interest Income00000
Interest Expense00000
Other Income / Expenses2.36M(10.43M)2.18M2.9M1.19M
Income Before Tax(9.29M)(15.68M)56.26M(17.7M)(66.93M)
Pre-Tax Margin-4.0%-4.0%13.9%-9.5%-58.2%
Income Tax Expense13.71M1.46M2.6M1.8M1.8M
Net Income(23M)(17.13M)53.66M(19.5M)(68.73M)
Net Margin-9.8%-4.4%13.2%-10.5%-59.8%
EPS (Basic)(0.32)(0.25)0.73(0.26)(0.94)
EPS (Diluted)(0.32)(0.25)0.72(0.26)(0.94)
Weighted Avg Shares71.98M72.51M73.35M74.43M73.49M
Weighted Avg Shares (Diluted)71.98M72.51M74.39M74.43M73.49M

OraSure Technologies, Inc.

NASDAQ:OSUR

Intrinsic Alpha fair value

Locked

Current Price

$3.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.